Kymera Therapeutics (KYMR) Non-Current Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Non-Current Assets data on file, last reported at $991.6 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 137.58% year-over-year to $991.6 million in Q1 2026; TTM through Mar 2026 was $2.8 billion, a 71.91% increase from a year earlier, with the FY2025 full-year figure at $871.6 million, up 86.33% from the prior year.
• Non-Current Assets for Q1 2026 stood at $991.6 million, up from $871.6 million in the prior quarter.
• Over the last five years, Non-Current Assets for KYMR reached as high as $991.6 million in Q1 2026 and fell as low as $120.7 million in Q2 2022.
• Historically, Non-Current Assets has averaged $361.7 million across 5 years, with a median of $300.6 million in 2024.
• Across the five-year window, Non-Current Assets retreated 7.23% in 2023 and soared 174.44% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $183.7 million in 2022, then slipped by 7.23% to $170.4 million in 2023, then surged by 174.44% to $467.8 million in 2024, then jumped by 86.33% to $871.6 million in 2025, then rose by 13.77% to $991.6 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $991.6 million in Q1 2026, $871.6 million in Q4 2025, and $573.7 million in Q3 2025.